Gilead highlights Yescarta survival data in ASCO updateGilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage Share XGilead highlights Yescarta survival data in ASCO updatehttps://pharmaphorum.com/news/gilead-highlights-yescarta-survival-data-in-asco-update/
Mustang Bio’s first-of-a-kind CAR-T starts trialsUS biotech Mustang Bio says that an investigator-led trial of its CAR-T therapy for multiple myeloma – the Share XMustang Bio’s first-of-a-kind CAR-T starts trialshttps://pharmaphorum.com/news/mustang-bio-car-t-starts-trials/
Janssen CAR-T is Priority Medicine in EU, and moreEuropean regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage Share XJanssen CAR-T is Priority Medicine in EU, and morehttps://pharmaphorum.com/views-analysis-oncology/janssen-car-t-is-priority-medicine-in-eu-and-more/
Cell Mogrify gets £420k funding for regenerative cell therapiesUK cell therapy company Cell Mogrify has been awarded £420,000 funding from Innovate UK to accelerate its data-driven Share XCell Mogrify gets £420k funding for regenerative cell therapieshttps://pharmaphorum.com/news/cell-mogrify-gets-420k-funding-for-regenerative-cell-therapies/
How T-cell therapy saved my lifeJudy Perkins’ stage 4 cancer was eradicated after she joined a clinical trial for T-cell therapy. She shares Share XHow T-cell therapy saved my lifehttps://pharmaphorum.com/views-analysis-patients/how-t-cell-therapy-saved-my-life/
Oncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerWill it happen or not? There are doubts about whether the proposed $74 billion merger of cancer drug Share XOncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerhttps://pharmaphorum.com/views-analysis-oncology/oncology-round-up-shareholders-question-bms-celgene-merger-while-merck-cos-keytruda-keeps-getting-stronger/
Gilead expands CAR-T deal with MaxCyte, Precision files for $100m IPOIt has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership Share XGilead expands CAR-T deal with MaxCyte, Precision files for $100m IPOhttps://pharmaphorum.com/news/gilead-expands-car-t-deal-with-maxcyte-precision-files-for-100m-ipo/
Market access roundup: UK HTA shakeups as Brexit fears deepenWith a Brexit deal still out of sight, there have been intensified warnings in the UK about potential Share XMarket access roundup: UK HTA shakeups as Brexit fears deepenhttps://pharmaphorum.com/views-and-analysis/market-access-roundup-uk-hta-shakeups-as-brexit-fears-deepen/
Medicare coverage for CAR-T drugs on the horizonMedicare could soon cover CAR-T therapies under new proposals from the US’ Centers for Medicare & Medicaid Services Share XMedicare coverage for CAR-T drugs on the horizonhttps://pharmaphorum.com/news/medicare-coverage-for-car-t-drugs-on-the-horizon/
